T1	PROC 46 139	Estudio multicéntrico aleatorizado, doble ciego, controlado con placebo, con grupos paralelos
T2	PROC 611 647	Consentimiento informado por escrito
#1	AnnotatorNotes T2	C0811741; Obtain informed written consent; Health Care Activity
T3	PROC 146 177	evaluar la eficacia y seguridad
#2	AnnotatorNotes T3	C0511730; Identify product efficacy and safety issues; Health Care Activity
T4	CHEM 181 191	Omalizumab
#3	AnnotatorNotes T4	C0966225; omalizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	CHEM 193 199	Xolair
#4	AnnotatorNotes T5	C1174773; Xolair; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	DISO 228 249	urticaria colinérgica
#5	AnnotatorNotes T6	C0152230; Cholinergic urticaria; Disease or Syndrome
T7	DISO 273 294	Urticaria colinérgica
#6	AnnotatorNotes T7	C0152230; Cholinergic urticaria; Disease or Syndrome
T8	PROC 377 388	diagnóstico
#7	AnnotatorNotes T8	C0011900; Diagnosis; Diagnostic Procedure
T9	DISO 392 413	urticaria colinérgica
#8	AnnotatorNotes T9	C0152230; Cholinergic urticaria; Disease or Syndrome
T10	PROC 448 469	prueba de provocación
#9	AnnotatorNotes T10	C0006265; Bronchial Provocation Tests; Diagnostic Procedure
T11	CHEM 523 539	antihistamínicos
#10	AnnotatorNotes T11	C0019590; Histamine Antagonists; Organic Chemical · Pharmacologic Substance
T12	DISO 687 707	enfermedad sistémica
#11	AnnotatorNotes T12	C0442893; Systemic disease; Disease or Syndrome
T13	PROC 725 736	seguimiento
#12	AnnotatorNotes T13	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T14	PROC 773 784	Tratamiento
#13	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	CHEM 789 799	omalizumab
#14	AnnotatorNotes T15	C0966225; omalizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T16	DISO 843 853	dermatitis
#15	AnnotatorNotes T16	C0011603; Dermatitis; Disease or Syndrome
T17	DISO 862 889	enfermedades dermatológicas
#16	AnnotatorNotes T17	C0037274; Dermatologic disorders; Disease or Syndrome
T18	DISO 906 913	prurito
#17	AnnotatorNotes T18	C0033774; Pruritus; Sign or Symptom
T19	DISO 988 1005	hipersensibilidad
#18	AnnotatorNotes T19	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T20	CHEM 1042 1053	excipientes
#19	AnnotatorNotes T20	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T21	DISO 1162 1173	alcoholismo
#20	AnnotatorNotes T21	C0001973; Alcoholic Intoxication, Chronic; Mental or Behavioral Dysfunction
T22	DISO 1175 1187	drogadicción
#21	AnnotatorNotes T22	C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T23	CHEM 1009 1025	principio activo
#22	AnnotatorNotes T23	C1372955; Active ingredient; Chemical Viewed Functionally
T24	Date 13 17	2013
T25	LIVB 323 350	Pacientes mujeres y hombres
#23	AnnotatorNotes T25	C0030705; Patients; Patient or Disabled Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T28	Age 351 369	mayores de 14 años
T30	Dose 555 578	2 veces la dosis máxima
T31	Duration 803 826	los 12 meses anteriores
T32	PHYS 1057 1065	Embarazo
#24	AnnotatorNotes T32	C0032961; Pregnancy; Organism Function
T33	PHYS 1068 1077	lactancia
#25	AnnotatorNotes T33	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T26	Dose 495 519	dosis supra terapéuticas
A1	Status T14 History_of
A2	Status T15 History_of
A3	Status T19 History_of
A4	Assertion T23 Contraindicated
A5	Assertion T20 Contraindicated
#26	AnnotatorNotes T1	C0013072; Double-Blind Method; Research Activity + C1096776; Multicenter Study; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product  + C2826345; Parallel Study; Research Activity
T27	Neg_cue 482 484	No
T29	Observation 485 494	respondan
A6	Assertion T29 Negated
T34	Neg_cue 1112 1119	impedir
T35	Observation 1123 1155	correcto cumplimiento del ensayo
A7	Assertion T35 Negated
R1	Negation Arg1:T34 Arg2:T35	
R2	Overlap Arg1:T35 Arg2:T21	
R3	Overlap Arg1:T35 Arg2:T22	
R4	Has_Age Arg1:T25 Arg2:T28	
T36	CONC 429 445	historia clínica
#27	AnnotatorNotes T36	C5204342; Clinical History; Intellectual Product
T37	Result_or_Value 470 478	positiva
#28	AnnotatorNotes T37	C1446409; Positive; Finding
R5	Has_Result_or_Value Arg1:T10 Arg2:T37	
R6	Negation Arg1:T27 Arg2:T29	
#29	AnnotatorNotes T29	C1319171; Medication response; Finding
R7	Overlap Arg1:T29 Arg2:T11	
R8	Has_Dose_or_Strength Arg1:T11 Arg2:T26	
R9	Has_Dose_or_Strength Arg1:T11 Arg2:T30	
R11	Used_for Arg1:T15 Arg2:T14	
R12	Has_Duration_or_Interval Arg1:T15 Arg2:T31	
R13	Overlap Arg1:T16 Arg2:T18	
R14	Overlap Arg1:T17 Arg2:T18	
R15	Causes Arg1:T23 Arg2:T19	
R16	Causes Arg1:T20 Arg2:T19	
R17	Before Arg1:T10 Arg2:T8	
A8	Experiencer T25 Patient
